BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ApaTech Ltd Announces US$45m Fund Raising


6/16/2008 12:42:08 PM

ApaTech, a world leader in applying the science of silicon to bone graft technology, is delighted to announce the successful completion of a US$45 million fundraising. The proceeds of the round, led by 3i plc and new investor HealthCor Partners, are to be invested in additional commercial resources, further clinical and new product development and a significant expansion of manufacturing capacity.

CEO Simon Cartmell said “These funds allow us to continue the successful development of ApaTech into a world leading orthobiologics company. We see significant potential in Actifuse and the portfolio of new technologies we are developing and I am delighted we have been able to secure investment from, and involvement of, two world class financial institutions who clearly share our vision of the future.”

As a result of the investment the Board of Directors will change significantly. Peter Chambré becomes Non-Executive Chairman, with Dr Nigel Pitchford and Michael Mashaal, MD joining the Board as investor directors on behalf of 3i plc and HealthCor respectively. Peter Chambré, who as CEO of Cambridge Antibody Technology plc oversaw its successful development and ultimately its sale to AstraZeneca plc for $1.4bn in 2006, said “I am delighted to be joining the ApaTech Board and to be able to help guide ApaTech through its next stage of rapid growth. It has differentiated technology, an exceptional management team and competes very successfully in a large and growing market by producing excellent outcomes for patients. This new funding will allow ApaTech to realize its potential as a world leading orthobiologics company over the next 3-4 years.” Nigel Gray, Chairman, David Holbrook of MTI, Keith Aldred representing Queen Mary, University of London and Renée Lucander of 3i Venture Capital will leave the Board. Professor Bill Bonfield remains as a non-executive director

Nigel Pitchford, a partner in 3i's healthcare team, said "We're proud to have been the long-term lead investor in ApaTech, from spin-out in 2001 through to the commercial success that it is today. With significant growth potential still ahead of it, we believe ApaTech continues to represent an outstanding opportunity. 3i is delighted to be able to invest substantial new funds and introduce an excellent new partner in HealthCor. Together we will provide ApaTech with the strong financial platform it needs to execute on the growth opportunity and become the worlds' leading orthobiologics company.”

Michael Mashaal, Managing Director of HealthCor, stated his support for the company’s growth plans. “We don’t often see companies with such strong potential in their existing and marketed portfolio. ApaTech clearly has the opportunity to grow rapidly over the next few years and we are delighted to be joining the ApaTech team at this exciting time. This funding will allow the Company to execute on its strategy as key differentiating clinical data becomes available.”

About ApaTech

ApaTech Limited, based in London, England, Foxborough, Mass. is a world leader in bone graft technologies. Founded in 2001 and based on research and intellectual property from Queen Mary University of London and Cambridge University, ApaTech has introduced a novel silicate substituted calcium phosphate bone graft material, Actifuse, globally. The company believes that Actifuse is the first of a new class of synthetic bone graft materials that combine osteoconductive and osteo-stimulatory activities and demonstrates the Company’s leadership in applying the science of silicon to bone graft technologies.

The Company raised $23m of equity from 3i plc and MTI and $7m of debt from Noble Venture Finance in 2001-7. ApaTech commercializes its products, Actifuse and ApaPore in 21 countries around the world and is achieving rapid sales growth, achieving sales of $15.5m in 2007.

ApaTech has locations in Elstree, UK, Berlin, Germany and Foxborough, MA, USA. The Company sells its products in the United States, UK, Germany and 18 other countries around the world. ApaTech was recently recognized as Britain’s fastest growing medical technology company in the 2007 Sunday Times Fast Track 100 fastest growing private companies review.

Further Information:

ApaTech
Simon Cartmell, CEO
+44 (0)20 8731 4640
simon.cartmell@apatech.com
www.apatech.com

3i
Rachel Richards, PR Manager
+44 (0) 20 7975 3573
rachel.richards@3i.com
www.3i.com

HealthCor
Elizabeth Miller
+1 212 622-7726
betsy@healthcorgroup.com
www.healthcorpartners.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES